Received Jun 11, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | F95HB | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | P2443 | — |
The patient had received the third dose on 04-DEC-2025; The first dose was given on 05-DEC-2025 and second dose was administered on 03-JUN-2025.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 54-year-old female patient who received HAB (Twinrix) suspension for injection in pre-filled syringe (batch number P2443 with expiry date 18-SEP-2027 and batch number F95HB with expiry date 29-MAY-2028) for prophylaxis. Concomitant products included HEPATITIS A VACCINE INACT;HEPATITIS B VACCINE RHBSAG (YEAST) (TWINRIX). On 04-DEC-2025, the patient received the 3rd dose of Twinrix. On 03-JUN-2025, not applicable after receiving Twinrix and an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: The first dose was given on 05-DEC-2025 and second dose was administered on 03-JUN-2025.). On 04-DEC-2025, the patient experienced drug dose administration interval too long (Verbatim: The patient had received the third dose on 04-DEC-2025).The outcome of the drug dose administration interval too long and drug dose administration interval too short were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 01-JUN-2026 The patient had received the second dose of Twinrix three weeks after the first dose. The pharmacist asked whether the patient should received another dose.
TWINRIX